BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 23101500)

  • 1. Non-coding RNA ANRIL and the number of plexiform neurofibromas in patients with NF1 microdeletions.
    Mußotter T; Kluwe L; Högel J; Nguyen R; Cooper DN; Mautner VF; Kehrer-Sawatzki H
    BMC Med Genet; 2012 Oct; 13():98. PubMed ID: 23101500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of noncoding RNA ANRIL in genesis of plexiform neurofibromas in neurofibromatosis type 1.
    Pasmant E; Sabbagh A; Masliah-Planchon J; Ortonne N; Laurendeau I; Melin L; Ferkal S; Hernandez L; Leroy K; Valeyrie-Allanore L; Parfait B; Vidaud D; Bièche I; Lantieri L; Wolkenstein P; Vidaud M;
    J Natl Cancer Inst; 2011 Nov; 103(22):1713-22. PubMed ID: 22034633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-Coding RNA and Tumor Development in Neurofibromatosis Type 1:
    Tritto V; Ferrari L; Esposito S; Zuccotti P; Bianchessi D; Natacci F; Saletti V; Eoli M; Riva P
    Genes (Basel); 2019 Nov; 10(11):. PubMed ID: 31694342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deregulated expression of polycomb repressive complex 2 target genes in a NF1 patient with microdeletion generating the RNF135-SUZ12 chimeric gene.
    Tritto V; Grilli F; Milani D; Riva P
    Neurogenetics; 2023 Jul; 24(3):181-188. PubMed ID: 37145209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genotype-phenotype correlation in neurofibromatosis type-1: NF1 whole gene deletions lead to high tumor-burden and increased tumor-growth.
    Well L; Döbel K; Kluwe L; Bannas P; Farschtschi S; Adam G; Mautner VF; Salamon J
    PLoS Genet; 2021 May; 17(5):e1009517. PubMed ID: 33951044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of intratumor heterogeneity in Neurofibromatosis type 1 plexiform neurofibromas and neurofibromas with atypical features: Correlating histological and genomic findings.
    Carrió M; Gel B; Terribas E; Zucchiatti AC; Moliné T; Rosas I; Teulé Á; Ramón Y Cajal S; López-Gutiérrez JC; Blanco I; Castellanos E; Lázaro C; Stemmer-Rachamimov A; Romagosa C; Serra E
    Hum Mutat; 2018 Aug; 39(8):1112-1125. PubMed ID: 29774626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low mutation burden and frequent loss of CDKN2A/B and SMARCA2, but not PRC2, define premalignant neurofibromatosis type 1-associated atypical neurofibromas.
    Pemov A; Hansen NF; Sindiri S; Patidar R; Higham CS; Dombi E; Miettinen MM; Fetsch P; Brems H; Chandrasekharappa SC; Jones K; Zhu B; Wei JS; ; ; Mullikin JC; Wallace MR; Khan J; Legius E; Widemann BC; Stewart DR
    Neuro Oncol; 2019 Aug; 21(8):981-992. PubMed ID: 30722027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors.
    Beert E; Brems H; Daniëls B; De Wever I; Van Calenbergh F; Schoenaers J; Debiec-Rychter M; Gevaert O; De Raedt T; Van Den Bruel A; de Ravel T; Cichowski K; Kluwe L; Mautner V; Sciot R; Legius E
    Genes Chromosomes Cancer; 2011 Dec; 50(12):1021-32. PubMed ID: 21987445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of loss of heterozygosity in neurofibromatosis type 1-associated plexiform neurofibromas.
    Steinmann K; Kluwe L; Friedrich RE; Mautner VF; Cooper DN; Kehrer-Sawatzki H
    J Invest Dermatol; 2009 Mar; 129(3):615-21. PubMed ID: 18800150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Germline and somatic NF1 gene mutations in plexiform neurofibromas.
    Upadhyaya M; Spurlock G; Monem B; Thomas N; Friedrich RE; Kluwe L; Mautner V
    Hum Mutat; 2008 Aug; 29(8):E103-11. PubMed ID: 18484666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging genotype-phenotype relationships in patients with large NF1 deletions.
    Kehrer-Sawatzki H; Mautner VF; Cooper DN
    Hum Genet; 2017 Apr; 136(4):349-376. PubMed ID: 28213670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reprogramming Captures the Genetic and Tumorigenic Properties of Neurofibromatosis Type 1 Plexiform Neurofibromas.
    Carrió M; Mazuelas H; Richaud-Patin Y; Gel B; Terribas E; Rosas I; Jimenez-Delgado S; Biayna J; Vendredy L; Blanco I; Castellanos E; Lázaro C; Raya Á; Serra E
    Stem Cell Reports; 2019 Feb; 12(2):411-426. PubMed ID: 30713041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NF1 mutations in neurofibromatosis 1 patients with plexiform neurofibromas.
    Kluwe L; Friedrich RE; Korf B; Fahsold R; Mautner VF
    Hum Mutat; 2002 Mar; 19(3):309. PubMed ID: 11857752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical characterization of children and adolescents with NF1 microdeletions.
    Kehrer-Sawatzki H; Kluwe L; Salamon J; Well L; Farschtschi S; Rosenbaum T; Mautner VF
    Childs Nerv Syst; 2020 Oct; 36(10):2297-2310. PubMed ID: 32533297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expanding the clinical phenotype of individuals with a 3-bp in-frame deletion of the NF1 gene (c.2970_2972del): an update of genotype-phenotype correlation.
    Koczkowska M; Callens T; Gomes A; Sharp A; Chen Y; Hicks AD; Aylsworth AS; Azizi AA; Basel DG; Bellus G; Bird LM; Blazo MA; Burke LW; Cannon A; Collins F; DeFilippo C; Denayer E; Digilio MC; Dills SK; Dosa L; Greenwood RS; Griffis C; Gupta P; Hachen RK; Hernández-Chico C; Janssens S; Jones KJ; Jordan JT; Kannu P; Korf BR; Lewis AM; Listernick RH; Lonardo F; Mahoney MJ; Ojeda MM; McDonald MT; McDougall C; Mendelsohn N; Miller DT; Mori M; Oostenbrink R; Perreault S; Pierpont ME; Piscopo C; Pond DA; Randolph LM; Rauen KA; Rednam S; Rutledge SL; Saletti V; Schaefer GB; Schorry EK; Scott DA; Shugar A; Siqveland E; Starr LJ; Syed A; Trapane PL; Ullrich NJ; Wakefield EG; Walsh LE; Wangler MF; Zackai E; Claes KBM; Wimmer K; van Minkelen R; De Luca A; Martin Y; Legius E; Messiaen LM
    Genet Med; 2019 Apr; 21(4):867-876. PubMed ID: 30190611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NF1 microdeletions in neurofibromatosis type 1: from genotype to phenotype.
    Pasmant E; Sabbagh A; Spurlock G; Laurendeau I; Grillo E; Hamel MJ; Martin L; Barbarot S; Leheup B; Rodriguez D; Lacombe D; Dollfus H; Pasquier L; Isidor B; Ferkal S; Soulier J; Sanson M; Dieux-Coeslier A; Bièche I; Parfait B; Vidaud M; Wolkenstein P; Upadhyaya M; Vidaud D;
    Hum Mutat; 2010 Jun; 31(6):E1506-18. PubMed ID: 20513137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NF1 patient missense variants predict a role for ATM in modifying neurofibroma initiation.
    Yu Y; Choi K; Wu J; Andreassen PR; Dexheimer PJ; Keddache M; Brems H; Spinner RJ; Cancelas JA; Martin LJ; Wallace MR; Legius E; Vogel KS; Ratner N
    Acta Neuropathol; 2020 Jan; 139(1):157-174. PubMed ID: 31664505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allelic loss of the NF1 gene in NF1-associated plexiform neurofibromas.
    Kluwe L; Friedrich RE; Mautner VF
    Cancer Genet Cytogenet; 1999 Aug; 113(1):65-9. PubMed ID: 10459349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Classification of NF1 microdeletions and its importance for establishing genotype/phenotype correlations in patients with NF1 microdeletions.
    Kehrer-Sawatzki H; Cooper DN
    Hum Genet; 2021 Dec; 140(12):1635-1649. PubMed ID: 34535841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mosaic Neurofibromatosis Type 1 With Multiple Cutaneous Diffuse and Plexiform Neurofibromas of the Lower Leg.
    Friedrich RE; Hagel C; Kohlrusch FK; Schanze I; Wieland I; Zenker M
    Anticancer Res; 2020 Jun; 40(6):3423-3427. PubMed ID: 32487640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.